| MERGERS, ACQUISITIONS & ASSET SALES |
| Acquiring Company |
Target(s) |
Deal Summary |
| Qiagen |
NeuMoDx |
- Price: $234 million
- Status: Merger agreement signed giving Qiagen right to acquire remaining 80% of NeuMoDx it doesn’t currently own
- Merger accompanied by strategic alliance under which Qiagen to market NeuMoDx 288 (high-throughput) and NeuMoDx 96 (mid-throughput) systems in Europe and other markets outside US
|
| Thermo Fisher Scientific |
Becton Dickinson’s Advanced Bioprocessing business |
- Price: Undisclosed
- Status: Expected to close in early 2019
- Thermo Fisher to integrate Advanced Bioprocessing into its life sciences solutions segment
|
| 10x Genomics |
Epinomics |
- Price: Undisclosed
- Status: Closed
- Acquisition of Stanford Univ. startup to commercialize technology for mapping chromatin regions across the genome
|
Summit Health
(Quest Diagnostics wellness sub) |
Hooper Holmes, dba, Provant Health |
- Price: $27 million
- Status: Stalking horse bid entered before and to be completed after bankruptcy auction in Oct.
- Target filed for Chapter 11 after 2017 merger of Hooper Holmes and Provant Health left combined company with a working capital shortfall and over-leveraged balance sheet
|
| Bruker |
Hain Lifescience |
- Price: Undisclosed
- Status: Bruker to acquire 80% interest with 2021 option for remaining 20%
- Bruker strengthens its tuberculosis and mycobacteria testing and human genetics capabilities by acquiring German molecular DX firm
|
| Canon Medical Systems |
ACTmed |
- Price: Undisclosed
- Status: Closed
- Canon acquires majority interest in Japanese joint venture between ACTmed and Taiwanese molecular DX firm ACT Genomics, including latter’s NGS technology
|
| Cancer Genetics |
NovellusDx |
- Price: Undisclosed
- Status: Merger agreement signed
- CGI’s cancer test products to be combined with NovellusDx’s NGS and machine-learning cancer treatment response prediction technologies
|
| Medicover |
Center for Human Genetics and Laboratory Diagnostics + IMGM Laboratories affiliate |
- Price: Undisclosed
- Status: Expected to close in Jan 2019
- Medicover acquires German labs known for genetic testing, pathology, transfusion medicine, microbiology and virology
|
| Inscripta |
Solana Biosciences |
- Price: Undisclosed
- Status: No closing date given
- Acquisition boosts Inscripta’s efforts to commercialize its gene editing tools
|
| STRATEGIC ALLIANCES, PARTNERSHIPS & COLLABORATIONS |
| Partner 1 |
Partner 2 |
Deal Summary |
| Predicine |
Flagship Biosciences |
- Objective: Offer integrated molecular and contextual tissue biomarker solution for immuno-oncology pharm customers
- Dynamic: Combine Predicine GeneRADAR combined liquid biopsy assay with Flagship’s artificial intelligence-enabled cTA digital pathology platform
|
| IDbyDNA |
Fleury Group (Brazil) |
- Objective: Offer IDbyDNA’s Explify platform for clinical metagenomic testing in South America
- Dynamic: Fleury to integrate Explify into its lab workflow to develop full suite of Explify-based clinical testing, starting with Explify Respiratory
|
| Qiagen |
NeuMoDx |
- Objective: Commercialize NeuMoDx’s PCR-based molecular diagnostic systems
- Dynamic: Qiagen to initially distribute the NeuMoDx 288 (high-throughput) and NeuMoDx 96 (mid-throughput) systems in Europe and other non-US markets
- Parties also signed a companion merger agreement (see M&A above)
|
| Natera |
Bristol-Myers Squibb |
- Objective: Determine if Natera’s circulating tumor DNA assay, Signatera, can identify non-small cell cancer patients who may benefit from BMS’s Opdivo (nivolumab) immunotherapy
- Dynamic: BMS researchers to use Signatera to select patients with minimal residual disease to receive standard of care adjuvant therapy or adjuvant therapy plus Opdivo
|
| Definiens |
Merck KGaA |
- Objective: Biomarker development
- Dynamic: Merck’s to use Definiens’ web-based collaboration software platform to support its use of Definiens’ Tissue Phenomics image-analysis technologies for biomarker quantification including immuno-profiling
|
| Celmatix |
Ferring Pharmaceuticals |
- Objective: Research women’s response to in vitro fertilization treatment
- Dynamic: Use Celmatix’s knowledgebase to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics
|
| Fluidigm |
Visiopharm |
- Objective: Comarket automated image analysis for imaging mass cytometry
- Dynamic: Copromote Visiopharm’s Phenomap image-analysis software with Fluidigm’s Hyperion imaging system, MCD Viewer software and Maxpar antibodies and kits
|
| Fluidigm |
GenomOncology |
- Objective: Create Immuno-Oncology Gene Expression Workflow for developing checkpoint immunotherapies and identifying predictive biomarker signatures for therapeutic response
- Dynamic: Combine Fluidigm Advanta Immuno-Oncology Gene Expression Assay with GenomOncology’s data analysis software
|
| Prescient Medicine |
Metabiomics |
- Objective: Develop microbiome diagnostic assays for colon cancer
- Dynamic: Use Metabiomics MultiTag NGS technology and microbiome analytics platform to develop stool-based test for precancerous colon polyps
- Sides will also work together to develop diagnostics for other GI diseases including Crohn’s disease, colitis and irritable bowel syndrome
|
| Novacyt |
Applied Microarrays (AMI) |
- Objective: Develop microarray-based SNP assays
- Dynamic: Novacyt’s Primerdesign molecular testing division to help AMI design probes for customized SNP microarrays used in point-of-care and lab settings
|
| BioArctic |
Brain Biomarker Solutions |
- Objective: Develop biomarkers and diagnostics for Alzheimer’s disease
- Dynamic: Sides to identify and measure new blood- and cerebrospinal fluid-based biomarkers that can be used to diagnose and monitor the effects of investigational treatments for Alzheimer’s
- Each side to bear its own costs, jointly own rights to resulting products and evenly split licensing revenues
|
| MRM Proteomics |
Exactis Innovation |
- Objective: Develop proteomic test for guiding cancer immunotherapy
- Dynamic: Use MRM’s immunoMALDI system to analyze breast and colorectal cancer samples in Exactis’ Personalize My Treatment patient registry to identify and validate protein markers predictive of patient response to cancer immunotherapies
|
| Foundation Medicine |
Incyte |
- Objective: Develop and commercialize companion diagnostics
- Dynamic: Start with a CDx for Incyte’s FGFR1/2/3 inhibitor, pemigatinib, for treating cholangiocarcinoma patients CDx for Incyte’s FGFR1/2/3 inhibitor, pemigatinib, to treat patients with cholangiocarcinoma, to be incorporated into Foundation’s FoundationOne CDx assay
|
| Seven Bridges Genomics |
E-Nios (Greece) |
- Objective: More efficient extraction of biomarker signatures from NGS and multi-omics data
- Dynamic: Combine machine learning and physiology to automate at least part of laborious process of interpreting potential biomarkers
|
| Lunaphore Technologies |
A. Menarini Diagnostics |
- Objective: Market system for personalized immunohistochemistry (IHC) treatment
- Dynamic: System to use Lunaphore’s LabSat Frozen technology for rapid enabling of IHC assays
|
| Exact Imaging |
Cambridge Consultants |
- Objective: Improve prostate cancer detection and diagnosis
- Dynamic: Combine Exact Imaging’s ExactVu micro-ultrasound platform for urologist to assess and target suspicious regions during biopsy with Cambridge’s AI and deep learning expertise
|
| Evotec |
Celgene |
- Objective: Targeted protein degradation drug discovery
- Dynamic: Use Evotec Panomics genomic, transcriptomic, and proteomic data platform to identify difficult-to-track drug targets
- Celgene to get exclusive rights to all drug candidates and pay Evotec undisclosed upfront payment, milestone payments and potential double-digit royalties
|
| Evotec |
Centogene |
- Objective: Develop high-throughput platform for evaluating novel small molecule treatments for rare hereditary metabolic diseases
- Dynamic: Combine Evotec’s induced pluripotent stem cell-based drug screening platform with Centogene’s patient access and biomarker expertise
|
| NRGene |
RCK (Israeli cannabis producer) |
- Objective: Develop DNA biomarkers for medical cannabis breeding and strain identification
- Dynamic: Use NRGene’s computational tools to develop the biomarkers for commercial use
|
| LTS Health |
The Project Santa Fe Foundation |
- Objective: Create online platform to serve as a knowledgebase to crowdsource ideas from health professionals and institutions in lab diagnostics
- Dynamic: Platform to launch in Nov.
|
| Agendia |
GeneCast Biotechnology |
- Objective: Bring Agendia’s breast cancer tests to China market
- Dynamic: GeneCast gets exclusive right to market Agendia MammaPrint and BluePrint tests in China referred by local physicians to be performed at GeneCast’s oncology laboratory
|
| Congenica |
Digital China Health Technologies (DC Health) |
- Objective: Bring Congenica’s Sapientia genome analysis platform to China market
- Dynamic: DC Health to market platform which will be tailored for Chinese market
|
| Biocartis |
Wondfo Biotech |
- Objective: Bring Biocartis’ Idylla platform to China market
- Dynamic: Form 50/50 joint venture to license Idylla in China starting by end of 2018
|
| Clearbridge Health’s SAM Laboratory subsidiary |
Indonesian firms PT Kreasi Putra Nusantara +
PT Indo Genesis Medika |
- Objective: Provide diagnostics services to public hospitals in Indonesia
- Dynamic: Multiple contracts under which SAM acquires proposed subscription of a controlling stake in Indo Genesis for $2.8 million
|
| Sienna Cancer Diagnostics |
Royal Melbourne Hospital (RMH) |
- Objective: Evaluate Sienna’s cancer hTERT for detecting telomerase biomarker for thyroid cancer
- Dynamic: Study to be conducted at RMH will run the test on fine needle aspirate thyroid biopsies with matched thyroid nodules after removal to determine whether it can accurately differentiate benign from cancerous nodules
|
| Biocept |
Highmark Health |
- Objective: Study clinical and economic impact of Biocept’s Target Selector liquid biopsy in patients with non-small cell lung cancer
- Dynamic: 12-month study conducted through Highmark’s Vital Innovation Program
|
| Abreos Biosciences |
ResearchDx |
- Objective: Make co-developed moNATor test for monitoring Tysabri (natalizumab) available to clinicians and researchers
- Dynamic: Test to be available through ResearchDx’s Pacific Diagnostics reference laboratory
|
| BGI |
Xing Technology (Australia) |
- Objective: Optimize DNA nanoball technology to improve quality and throughput of sequencing data to lower costs
- Dynamic: Collaborate on integrating circulating tumor cell isolation, characterization and sequencing to accelerate technology’s use for disease screening and monitoring
- Jointly research and manufacture a diagnostic product developed by Xing
|
| DISTRIBUTION, SALES & MARKETING AGREEMENTS |
| Property Owner |
Distributor |
Deal Summary |
| Arbor Biosciences |
Tataa Biocenter |
- Products: Arbor’s NGS and synthetic biology products
- Territories: Sweden, Denmark, Norway, Slovakia, Czech Republic
- Arbor to provide reagents and support to Tataa for its education course on NGS applications
|
| Ranomics |
Axil Scientific |
- Product: Ranomics’ VariantFind DNA libraries
- Territory: Singapore
|
| HalioDx |
Gencell Pharma |
- Product: HalioDx’s Immunoscore Colon assay
- Territory: Colombia
- HalioDx made distribution deals for assay in Mexico and Israel in July
|
| Lucence Diagnostics |
Mascots Medical and Laboratory Center |
- Products: Lucence’s blood-based cancer diagnostic tests and treatment in
- Territory: Myanmar
- Lucence has deals already in place for Philippines, Thailand and Singapore
|
| Todos Medical |
Orot+ |
- Products: Todos’ blood-based breast cancer screening tests TM-B1 and TM-B2
- Territories: Romania (5 years) and Austria (3 years)
- Exclusive
|
| NovellusDx |
Primetech |
- Product: NovellusDx’s functional annotation for cancer treatment (FACT) assay
- Territory: Japan
- Exclusive
|
| LICENSES |
| Licensor |
Licensee |
Deal Summary |
| Illumina |
Premaitha Health |
- Property: Illumina’s NIPT patent pool
- Premaitha to offer testing in Europe and other countries and develop a version of its Iona test
- Premaitha to also pay up to £1 million ($1.3 million) to settle its UK litigation with Illumina
|
| Broad Institute and ERS Genomics |
Thermo Fisher Scientific |
- Property: CRISPR technologies patents
- Global, non-exclusive
|
| Hospital Del Mar + two individual researchers from University of Torino |
Biocartis |
- Property: EGFR ectodomain mutations that have been shown to determine responses to targeted therapy for metastatic colorectal cancer
- Global, exclusive
|
| Nanosys |
BioDirection |
- Property: Patents for technologies BioDirection is using to develop its development of its Tbit sepsis diagnostic platform
- Extension of 2012 agreement between the parties
- Global, exclusive
|
| SUPPLY, SERVICE & TESTING AGREEMENTS |
| Supplier/Servicer |
Client/User |
Deal Summary |
| NeoGenomics |
Premier |
- Group purchasing agreement providing Premier network members access to NeoGenomics clinical reference lab testing services at pre-set rates
|
| Expedeon |
PaxGenBio (South Korea) |
- 3-year license and supply agreement under which Expedeon to supply PaxGenBio colloidal gold for use in multiplexed polymerase chain reaction-based universal lateral flow assays for simultaneous detection of sexually transmitted diseases and tuberculosis
|
